| 2025-11-21 |
详情>>
内部人交易：
Madsen Julia共交易4笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本9814.70万股
|
| 2025-11-06 |
详情>>
业绩披露：
2026年中报每股收益3.75美元,归母净利润3.69亿美元,同比去年增长24.97%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘后发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2026年一季报每股收益1.80美元,归母净利润1.77亿美元,同比去年增长22.01%
|
| 2025-06-12 |
股东大会：
将于2025-07-31召开股东大会
会议内容 ▼▲
- 1.To elect directors of the Company:a)To re-elect Dr. Esther M. Alegria as a director of the Company.b)To re-elect Richard C. Breeden as a director of the Company.c)To re-elect Daniel A. Carestio as a director of the Company.d)To re-elect Cynthia L. Feldmann as a director of the Company.e)To re-elect Christopher S. Holland as a director of the Company.f)To re-elect Paul E. Martin as a director of the Company.g)To re-elect Dr. Nirav R. Shah as a director of the Company.h)To elect Louis A. Shapiro as a director of the Company.i)To re-elect Dr. Mohsen M. Sohi as a director of the Company.j)To re-elect Dr. Richard M. Steeves as a director of the Company.
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2026.
3.To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
4.To authorize the Board of Directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
5.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the SEC, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s Proxy Statement dated June 12, 2025.
6.To approve the renewal of the Board’s authority to issue authorized but unissued shares under Irish law (i) in an amount of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of June 2, 2025 (the “Record Date”) and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
7.To approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash (i) in respect of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of the Record Date), provided that, insofar as it relates to shares which represent greater than 10% in number of STERIS’s issued ordinary share capital (calculated as of the Record Date), such authority be used only for purposes of an acquisition or a specified capital investment, and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
8.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2025-05-29 |
详情>>
业绩披露：
2023年年报每股收益1.07美元,归母净利润1.07亿美元,同比去年增长-56.12%
|
| 2025-05-29 |
详情>>
业绩披露：
2025年年报每股收益6.24美元,归母净利润6.15亿美元,同比去年增长62.50%
|
| 2025-02-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益4.75美元,归母净利润4.69亿美元,同比去年增长23.54%
|
| 2024-11-07 |
详情>>
业绩披露：
2025年中报每股收益2.99美元,归母净利润2.95亿美元,同比去年增长23.68%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年一季报每股收益1.25美元,归母净利润1.24亿美元,同比去年增长11.05%
|
| 2024-08-08 |
详情>>
业绩披露：
2025年一季报每股收益1.47美元,归母净利润1.45亿美元,同比去年增长17.68%
|
| 2024-06-12 |
股东大会：
将于2024-08-01召开股东大会
会议内容 ▼▲
- 1.Ordinary resolutions to elect directors of the Company:(a)To re-elect Dr. Esther M. Alegria as a director of the Company. (b)To re-elect Richard C. Breeden as a director of the Company.(c)To re-elect Daniel A. Carestio as a director of the Company.(d)To re-elect Cynthia L. Feldmann as a director of the Company.(e)To re-elect Christopher S. Holland as a director of the Company.(f)To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.(g)To re-elect Paul E. Martin as a director of the Company.(h)To re-elect Dr. Nirav R. Shah as a director of the Company.(i)To re-elect Dr. Mohsen M. Sohi as a director of the Company.(j)To re-elect Dr. Richard M. Steeves as a director of the Company.
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2025.
3.To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
4.To authorize the Board of Directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
5.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the SEC, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s Proxy Statement dated June 12, 2024.
6.To approve the renewal of the Board’s authority to issue authorized but unissued shares under Irish law (i) in an amount of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of June 3, 2024) and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
7.To approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash (i) in respect of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of June 3, 2024), provided that, insofar as it relates to shares which represent greater than 10% in number of STERIS’s issued ordinary share capital (calculated as of June 3, 2024), such authority be used only for purposes of an acquisition or a specified capital investment, and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
8.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2024-05-29 |
详情>>
业绩披露：
2024年年报每股收益3.83美元,归母净利润3.78亿美元,同比去年增长253.40%
|
| 2024-02-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益3.84美元,归母净利润3.80亿美元,同比去年增长573.37%
|
| 2023-11-07 |
详情>>
业绩披露：
2024年中报每股收益2.42美元,归母净利润2.39亿美元,同比去年增长217.08%
|
| 2023-08-02 |
复牌提示：
2023-08-02 09:37:13 停牌，复牌日期 2023-08-02 09:42:13
|
| 2023-06-07 |
股东大会：
将于2023-07-27召开股东大会
会议内容 ▼▲
- 1.Ordinary resolutions to elect directors of the Company:(a)To re-elect Dr. Esther M. Alegria as a director of the Company. (b)To re-elect Richard C. Breeden as a director of the Company.(c)To re-elect Daniel A. Carestio as a director of the Company.(d)To re-elect Cynthia L. Feldmann as a director of the Company.(e)To re-elect Christopher S. Holland as a director of the Company.(f)To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.(g)To re-elect Paul E. Martin as a director of the Company.(h)To re-elect Dr. Nirav R. Shah as a director of the Company.(i)To re-elect Dr. Mohsen M. Sohi as a director of the Company.(j)To re-elect Dr. Richard M. Steeves as a director of the Company.
2.Ordinary resolution regarding ratification of independent registered public accounting firm:To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2024.
3.Ordinary resolution to appoint Ernst & Young Chartered Accountants as our Irish statutory auditor:To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
4.Ordinary resolution regarding our Irish statutory auditor’s remuneration:To authorize the Board of Directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
5.Advisory resolution (to be proposed as an ordinary resolution) on named executive officer compensation:To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the SEC, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s Proxy Statement dated June 7, 2023.
6.Advisory resolution (to be proposed as an ordinary resolution) on the frequency of the shareholder advisory vote on named executive officer compensation:To approve, on a non-binding advisory basis, whether the non-binding advisory vote on named executive officer compensation should be held every one, two, or three years.
7.Ordinary resolution regarding the renewal of the Board’s authority to issue shares under Irish law:To approve the renewal of the Board’s authority to issue authorized but unissued shares under Irish law (i) in an amount of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of May 30, 2023) and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
8.Special resolution regarding the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law:To approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash (i) in respect of up to 20% of the existing issued ordinary share capital of STERIS (calculated as of May 30, 2023), provided that, insofar as it relates to shares which represent greater than 10% in number of STERIS’s issued ordinary share capital (calculated as of May 30, 2023), such authority be used only for purposes of an acquisition or a specified capital investment, and (ii) until the earlier of the next annual general meeting of shareholders or the expiration of 15 months from the Annual Meeting.
9.Other business:To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2022-06-07 |
股东大会：
将于2022-07-28召开股东大会
会议内容 ▼▲
- 1.Ordinary resolutions to elect directors of the Company:(a)To re-elect Richard C. Breeden as a director of the Company.(b)To re-elect Daniel A. Carestio as a director of the Company.(c)To re-elect Cynthia L. Feldmann as a director of the Company.(d)To re-elect Christopher S. Holland as a director of the Company.(e)To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.(f)To re-elect Paul E. Martin as a director of the Company.(g)To re-elect Dr. Nirav R. Shah as a director of the Company.(h)To re-elect Dr. Mohsen M. Sohi as a director of the Company.(i)To re-elect Dr. Richard M. Steeves as a director of the Company.
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2023.
3.To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
4.To authorize the board of directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
5.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission (the “SEC”), including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 14, 2022.
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-07 |
股东大会：
将于2021-07-29召开股东大会
会议内容 ▼▲
- 1.To re-elect Richard C. Breeden as a director of the Company.
2.To re-elect Daniel A. Carestio as a director of the Company.
3.To re-elect Cynthia L. Feldmann as a director of the Company.
4.To re-elect Christopher S. Holland as a director of the Company.
5.To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.
6.To re-elect Paul E. Martin as a director of the Company.
7.To re-elect Dr. Nirav R. Shah as a director of the Company.
8.To re-elect Dr. Mohsen M. Sohi as a director of the Company.
9.To re-elect Dr. Richard M. Steeves as a director of the Company.
10.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2022.
11.To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
12.To authorize the board of directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
13.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission (the “SEC”), including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 14, 2021.
14.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-06-05 |
股东大会：
将于2020-07-28召开股东大会
会议内容 ▼▲
- 1.Ordinary resolutions to elect directors of the Company:
a.To re-elect Richard C. Breeden as a director of the Company.
b.To re-elect Cynthia L. Feldmann as a director of the Company.
c.To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.
d.To re-elect David B. Lewis as a director of the Company.
e.To re-elect Walter M Rosebrough, Jr. as a director of the Company.
f.To re-elect Dr. Nirav R. Shah as a director of the Company.
g.To re-elect Dr. Mohsen M. Sohi as a director of the Company.
h.To re-elect Dr. Richard M. Steeves as a director of the Company.
2.Ordinary resolution regarding ratification of independent registered public accounting firm: To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2021.
3.Ordinary resolution to appoint Ernst & Young Chartered Accountants as our Irish statutory auditor:To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.
4.Ordinary resolution regarding our Irish statutory auditor’s remuneration:To authorize the board of directors of the Company (the “Board”) or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.
5.Advisory resolution (to be proposed as an ordinary resolution) on executive compensation:To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission (the “SEC”), including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2020.
6.Other business:To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-02-10 |
除权日：
美东时间 2020-02-24 每股派息0.37美元
|
| 2019-11-04 |
除权日：
美东时间 2019-11-25 每股派息0.37美元
|
| 2019-08-05 |
除权日：
美东时间 2019-09-09 每股派息0.37美元
|
| 2019-06-05 |
股东大会：
将于2019-07-30召开股东大会
会议内容 ▼▲
- 1.To re-elect Richard C. Breeden as a director of the Company.
2.To re-elect Cynthia L. Feldmann as a director of the Company.
3.To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.
4.To re-elect David B. Lewis as a director of the Company.
5.To re-elect Walter M Rosebrough, Jr. as a director of the Company.
6.To re-elect Dr. Nirav R. Shah as a director of the Company.
7.To re-elect Dr. Mohsen M. Sohi as a director of the Company.
8.To re-elect Dr. Richard M. Steeves as a director of the Company.
|
| 2019-05-13 |
除权日：
美东时间 2019-06-11 每股派息0.34美元
|
| 2018-06-05 |
股东大会：
将于2018-07-31召开股东大会
会议内容 ▼▲
- 1.To re-elect Richard C. Breeden as a director of the Company.
2.To re-elect Cynthia L. Feldmann as a director of the Company.
3.To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.
4.To re-elect David B. Lewis as a director of the Company.
5.To re-elect Sir Duncan K. Nichol as a director of the Company.
6.To re-elect Walter M Rosebrough, Jr. as a director of the Company.
7.To re-elect Dr. Nirav R. Shah as a director of the Company.
8.To re-elect Dr. Mohsen M. Sohi as a director of the Company.
9.To re-elect Dr. Richard M. Steeves as a director of the Company.
10.To re-elect Loyal W. Wilson as a director of the Company.
11.To re-elect Dr. Michael B. Wood as a director of the Company.
12.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2019.
13.To appoint Ernst & Young LLP as the Company’s U.K. statutory auditor under the Act to hold office until the conclusion of the Company’s next Annual General Meeting.
14.To authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young LLP as the Company’s U.K. statutory auditor.
15.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission (the “SEC”), including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2018.
16.To approve, on a non-binding advisory basis, the Director Remuneration Report for the period ended March 31, 2018 contained within the Company’s U.K. annual report and accounts for the year ended March 31, 2018.
17.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-06-05 |
股东大会：
将于2017-08-01召开股东大会
会议内容 ▼▲
- 1. To re-elect Richard C. Breeden as a director of the Company.
2. To re-elect Cynthia L. Feldmann as a director of the Company.
3. To re-elect Dr. Jacqueline B. Kosecoff as a director of the Company.
4. To re-elect David B. Lewis as a director of the Company.
5. To re-elect Sir Duncan K. Nichol as a director of the Company.
6. To re-elect Walter M Rosebrough, Jr. as a director of the Company.
7. To re-elect Dr. Mohsen M. Sohi as a director of the Company.
8. To re-elect Dr. Richard M. Steeves as a director of the Company.
9. To re-elect John P. Wareham as a director of the Company.
10. To re-elect Loyal W. Wilson as a director of the Company.
11. To re-elect Dr. Michael B. Wood as a director of the Company.
12. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2018.
13. To appoint Ernst & Young LLP as the Company’s U.K. statutory auditor under the Act to hold office until the conclusion of the Company’s next Annual General Meeting.
14. To authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young LLP as the Company’s U.K. statutory auditor.
15. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2017.
16. To approve, on a non-binding advisory basis, whether the non-binding advisory vote on executive compensation should be held every one, two, or three years.
17. To approve, on a non-binding advisory basis, the Directors’ Remuneration Report for the period ended March 31, 2017 contained within the Company’s U.K. annual report and accounts for the year ended March 31, 2017.
18. To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2016-06-13 |
股东大会：
将于2016-08-02召开股东大会
会议内容 ▼▲
- 1. To re-elect Richard C. Breeden as a director of the Company.
2. To re-elect Cynthia L. Feldmann as a director of the Company.
3. To re-elect Jacqueline B. Kosecoff as a director of the Company.
4. To re-elect David B. Lewis as a director of the Company.
5. To re-elect Sir Duncan K. Nichol as a director of the Company.
6. To re-elect Walter M Rosebrough, Jr. as a director of the Company.
7. To re-elect Mohsen M. Sohi as a director of the Company.
8. To re-elect Richard M. Steeves as a director of the Company.
9. To re-elect John P. Wareham as a director of the Company.
10. To re-elect Loyal W. Wilson as a director of the Company.
11. To re-elect Michael B. Wood as a director of the Company.
12. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending March 31, 2017.
13. To appoint Ernst & Young LLP as the Company's U.K. statutory auditor under the Act to hold office until the conclusion of the Company’s next Annual General Meeting.
14. To authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young as the Company's U.K. statutory auditor.
15. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 13, 2016.
16. To approve, on a non-binding advisory basis, the Directors’ Remuneration Report (other than the part containing the directors’ remuneration policy) for the period ended March 31, 2016 contained within the Company’s annual report and accounts for the year ended March 31, 2016.
17. To approve the Directors’ Remuneration Policy.
18. To approve the STERIS plc Senior Executive Management Incentive Compensation Plan, Effective April 1, 2016.
19. To approve the STERIS plc 2006 Long-Term Equity Incentive Plan, as Amended and Restated Effective August 2, 2016.
20. To (a) authorize the Company to make off-market purchases (within the meaning of section 694 of the Companies Act 2006); (b) approve the share repurchase contracts in the forms produced to the Meeting and initialed by the Chairman for the purposes of identification to be used by the Company to repurchase its ordinary shares of ￡0.10 per share (the "Ordinary Shares") pursuant to and in accordance with the terms set out therein; and (c) approve the list of counterparties with whom the Company may conduct such repurchase transactions. The authority conferred by this resolution shall expire on the fifth anniversary of the date of the 2016 Annual General Meeting of Shareholders, except that the Company may, before the expiration of the authority granted by this resolution, enter into a contract to purchase Ordinary Shares which will or may be executed wholly or partly after the expiration of such authority.
21. To authorize the Company to make an off-market purchase (within the meaning of section 694 of the Companies Act 2006) of the one Ordinary Share of the Company held by STERIS Corporation, and approve a share repurchase contract in the form produced to the Meeting and initialed by the Chairman for the purposes of identification to be used to effect such repurchase.
22. To approve the deletion of Article 154(1) of the Company’s Articles of Association relating to business combinations and its replacement with the following:
"The adoption or authorisation of any Business Combination must be pre-approved with the sanction of an ordinary resolution of the Company. The foregoing vote shall be in addition to any class vote or other vote otherwise required by law, these Articles, or any agreement to which the Company is a party."
23. To ratify and confirm:
a. the payment of $0.25 per Ordinary Share interim dividend made by the Company on March 29, 2016 (the "Interim Dividend") and the entry in the audited accounts of the Company for the fiscal year ended March 31, 2016, whereby distributable profits of the Company were appropriated to the payment of the Interim Dividend;
b. that any and all claims which the Company may have in respect of the payment of the Interim Dividend against its shareholders who appeared on the register of shareholders and/or against holders of depositary interests in respect of Ordinary Shares on the record date for the Interim Dividend be released effective as of March 29, 2016, and that a deed of release in favor of such persons be entered into by the Company in the form of the deed produced to the Meeting and initialed by the Chairman for the purposes of identification;
c. that any and all claims which the Company has or may have against its directors (whether past, present or future) arising in connection with the payment of the Interim Dividend be released and that a deed of release in favor of such persons be entered into by the Company in the form of the deed produced to the Meeting and initialed by the Chairman for the purposes of identification.
24. To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|